R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - Antibody (73)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a First-in-Class MSLN x GAS6 Trap Bispecific ADC Candidate for Pancreatic Cancer: Overcoming Antigen Shedding and Remodeling Tumor Microenvironment
Antibody PDAC MSLN & TAM Hit Seoul National University RS-2026-25503246
2 Pre-clinical Safety and Efficacy Validation of GB2Ab, an ‘Induced-fit’ GFRAL Receptor Antagonist, for Cancer Cachexia Treatment and Potentiating Immuno-Oncology Response
Antibody Cancer-associated cachexia (CAC) GFRAL (GDNF Family Receptor Alpha-Like) Candidate Thor therapeutics Inc. RS-2026-25503136
3 Development of a biopharmaceutical lead molecule for the treatment of EGFR-positive cancer using an innovative modality that targets tumor surface EGFR and intracellular oncoprotein CP2c
Antibody HNSCC, CRC, TNBC EGFR / CP2c Hit Konkuk University GLOCAL Industry-Academic Cooperation Foundation RS-2026-25502354
4 Development of a Novel ADC Candidate Targeting ITGB4 through Lead Optimization and Initiation of Preclinical Development
Antibody Solid Tumor ITGB4 Candidate Genome & Company RS-2026-25501836
5 PB203, A Triple-Target TME Disruptor (PD-L1/VEGF-A/PLGF): Next-generation immuno-oncology solution for pancreatic cancer, paving the way for refractory fibrotic/immune-excluded tumors.
Antibody PDAC (Gateway to NSCLC, TNBC, and immune-excluded/fibrotic solid tumors) PD-L1, VEGF-A, PLGF Preclinical Panolos Bioscience Inc. RS-2025-25455606
6 Non-Clinical Development of an Antibody-Drug Conjugate (ADC) Targeting RTK-like Receptors for the Treatment of Solid Tumors
Antibody Solid tumor undisclosed Preclinical Aimedbio Inc RS-2025-25455321
7 Development of Next-Generation HER2-Targeted ADC Candidates Employing NAMPT Inhibitor Payloads to Overcome Limitations of Current Therapies
Antibody Solid tumor NAMPT Candidate Samjin Pharmaceutical RS-2025-25454767
8 Development of YH32367, a novel HER2/4-1BB bispecific antibody for the treatment of HER2 expressing solid tumors
Antibody 1st indication: HER2-positive Biliary Tract Cancer Other Indications: HER2-expressing solid tumors​ HER2/4-1BB Phase 2 YUHAN RS-2025-25454580
9 Lead identification of TROP2 x PD-L1 x CD3 trispecific antibody using multi-body platform technology
Antibody NSCLC TROP2 x PD-L1 x CD3 Lead ARKGEN BioScions RS-2025-25450700
10 Lead generation of PD-1xVEGFxCTLA-4 trispecific antibody using UniStac platform
Antibody CRC, G/GEJ adenocarcinoma Cervical cancer PD-1, VEGF, CTLA-4 Lead Onegene Biotechnology RS-2025-25447260
11 Development of an ADC therapeutic candidate targeting the novel antigen *** for the treatment of solid tumors
Antibody HCC & SCLC *** Candidate Boostimmune RS-2025-25445446
12 Development of a Candidate Therapeutic Antibody Targeting CTHRC1 for the Treatment of Triple-Negative Breast Cancer
Antibody TNBC CTHRC1 Candidate Prestige Biopharma IDC RS-2025-25444331
13 Development of TME responding Probody CD3xCEACAM5 T-cell engager
Antibody Solid cancer CD3, CEACAM5 Candidate DAAN Biotherapeutics, Inc. RS-2025-02223296
14 Development of a Therapeutic Antibody Targeting TCTP for Refractory Colorectal Cancer
Antibody Colon cancer TCTP Preclinical 넥스아이 RS-2025-02213729
15 Non-clinical development of an antibody-drug conjugate(ADC) for solid tumors targeting Src kinase-related transmembrane proteins
Antibody Solid cancer Target A Preclinical Aimedbio Inc. RS-2025-02213655
16 Derivation of Trop2-Targeting Antibody-Cytokine Fusion Protein (anti-TROP2 ACFP) for Maximizing Anticancer Effects and Minimizing Side Effects
Antibody Solid cancer TROP2 Lead ABION. INC. RS-2025-02213236
17 Development of Lead Therapeutic Antibody-Drug Conjugate Targeting CDCP1 for Pancreatic Cancer Treatment
Antibody CDCP1 (+)-Pancreatic cancer CDCP1 Lead Novelty Nobility Inc. RS-2025-02192979
18 Development of a Lead ADC Targeting LRRC15 for the Cancer Cells and Cancer-associated Fibroblasts
Antibody Osteosarcoma, Colon cancer, malignant melanoma LRRC15 Lead EdisBiotech. Co., Ltd. RS-2025-02183052
19 Development of EGFR specific BiTE (bispecific T cell engager) for solid tumor treatment
Antibody EGFR high expressing cancer EGFR, CD3 Hit SNU R&DB Foundation RS-2025-02172968
20 Lead generation of HER3-ADC for the treatment of metastatic breast cancer
Antibody Metastatic breast cancer HER3 Lead IntoCell, Inc. RS-2024-00461865
21 Identification of Lead Candidate for PD-L1/*** Bispecific Antibody
Antibody Solid cancer PD-L1 and *** Lead GI Innovation Inc. RS-2024-00461392
22 Clinical phase I development for SCLC and GIST using antibodydrug conjugate targeting c-Kit
Antibody SCLC, GIST c-Kit Phase 1 Novelty Nobility Inc. RS-2024-00461295
23 "Preclinical development of a bispecific aPD-1/IL-2v immunotherapy with enhanced TME selectivity and safety via modulated IL-2Rγ affinity"
Antibody Solid tumor PD-1, IL-2 receptor in activated T cells Preclinical MustBio RS-2024-00459772
24 Discovery of novel anti-CD33 antibody-enabled GSPT1 degraders for treatment of relapsed and refractory AML
Antibody Acute myeloid leukemia GSPT1 Candidate Therapex Co., Ltd. RS-2024-00443425
25 CKD-ADC, A Novel Antibody-Drug Conjugate Targeting cMET in Solid Tumors
Antibody Non-small cell lung cancer cMET Preclinical Chong Kun Dang Pharmaceutical Corp. RS-2024-00442212
26 Lead generation of a first-in-class CD171 ADC against solid tumors
Antibody Solid tumor CD171 Lead APITBIO, Inc. RS-2024-00338745
27 Development of First-in-Class NK Cell Engagers Targeting Trop2NKp46 Incorporating ADCC Maximizing Fc Variants for the Treatment of Triple-Negative Breast Cancer
Antibody TNBC Trop-2, NKp46, CD16A Hit Korea University RS-2024-00337233
28 Nonclinical development of CTN001 for treating patients with breast cancer and gastric cancer
Antibody Breast cancer, Gastric cancer HER2 Preclinical Centenaire Bioscience, Inc. RS-2024-00336882
29 Development of a CD33.targeted lead antibody for the treatment of AML based on a novel innovative antibody platform technology
Antibody Cancer CD33 Lead Centenaire Biosciences RS-2023-00283660
30 Development of lead immunotherapy agent for cancer using IL.36 receptor agonist antibody
Antibody Melanoma IL.36 Hit Daegu Gyeongbuk Institute of Science & Technology(DGIST) RS-2023-00283446
31 Novel bispecific antibodies development for Metastatic CastrationResistant Prostate Cancer
Antibody Cancer PSMA/CD137 Lead Ab Clon Inc. RS-2023-00283056
32 Preclinical Development of Anti.FGFR3 ADC for the Treatment of Bladder Cancer and Brain Tumor
Antibody Glioblastoma FGFR3 Preclinical Aimedbio RS-2023-00282706
33 Development of antibody against specific target expressed in the tumor microenvironment
Antibody Cancer HGF Lead Seoul National University RS-2023-00258823
34 Development of tumor ECM.modifying bispecific antibody for cancer immunotherapy
Antibody TNBC, NSCLC, PC DDR1, TGF.β Hit POSTECH RS-2023-00258678
35 Preclinical study of CLDN18.2 targeting antibody-drug conjugate for gastric cancer treatment
Antibody Gastric cancer, Gastroesophageal junction edema cancer CLDN18.2 Preclinical AbTis Co., Ltd. RS-2023-00219493
36 Derivation of First-in-Class therapeutic antibody candidate for the treatment of claudin-3 overexpressing solid cancers
Antibody CLDN3hi solid cancer CLDN3 Candidate Abion, Inc. RS-2023-00218182
37 Generation of the lead antibody targeting APP, a novel immuno-oncology target
Antibody Solid cancer APP Lead Genome & Company RS-2023-00217717
38 Candidate development of anti-TCTP neutralizing candidate (BIO101) for the treatment of solid tumors
Antibody Solid Cancer TCTP Candidate Boostimmune, Inc. RS-2023-00217478
39 Development of a Novel Immunotherapeutics with Tumor-associated Macrophage(TAM) Suppression Mechanism
Antibody NSCLC CHI3L1 Lead Senelix RS-2022-00166446
40 Development of a new therapeutic agent for bone metastasis cancer through the development of anti-****** humanized antibody
Antibody Solid Tumor CXCL16 Hit Cellus RS-2022-00166371
41 IND approval and securing IMP batch for GENA-104A16, an immune checkpoint inhibitor targeting CNTN4
Antibody Solid Tumor CNTN4 Preclinical Genome&Company RS-2022-00166157
42 Development of hit/lead antibody neutralizing TMPRSS4, a novel therapeutic target for the treatment of non-small cell lung cancer
Antibody NSCLC TMPRSS4 Hit Korea Research Institute of Bioscience and Biotech RS-2022-00166100
43 Development for immunotherapeutics targeting tumor-associated macrophages
Antibody Solid Tumor TREM2 Lead AimedBio Inc RS-2022-00166068
44 Development of a non-clinical candidate for colorectal cancer treatment RACE-111 (EGFRX4-1BB) bispecific antibody
Antibody Colorectal cancer EGFR, 4-1BB Candidate CTCELLS RS-2022-00166009
45 Development of immuno-cancer antibodies that improves single and/or combination anti-cancer efficacy by improving immune suppressive tumor microenvironments
Antibody Solid Tumor B7-H3/TGF-β Candidate Theranotics HN22C0442
46 Preclinical development of ITC-6146RO, a B7-H3 targeting ADC, for the Treatment of Non-Small Cell Lung Cancer
Antibody NSCLC B7-H3 Preclinical IntoCell HN22C0373
47 Development of CD47/CD73 dual-target SAFAbody antibody therapy for the treatment of intractable solid cancer including triple-negative breast cancer
Antibody TNBC CD47, CD73 Hit AprilBio HN22C0297
48 Development of a first-in-class immunotherapy for treatment of non-small cell lung cancer with PD-L1 negative/low
Antibody Lung Cancer IGSF1 Preclinical Wellmarkerbio HN22C0157
49 Development of cancer cachexia treatment using anti-GFRAL antibody
Antibody Cancer Cachexia GFRAL Candidate TroyY HN22C0147
50 Development of complement C4d X CD3 BiTE
Antibody Cancer C4d, CD3 Hit Seoul National University HN22C0061
51 Candidate development of PD-L1xIL-2v immuno-oncology (MB201) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, IL-2 Candidate MustBio Inc HN22C0050
52 Nonclinical study of the immuno-oncological therapeutic antibody against novel immune checkpoint CD300c
Antibody Lung cancer, Colorectal, Breast cancer CD300c Preclinical CentricsBio Inc. HN21C1400
53 Completion of YBL-006 phase I trial; 
a novel immune checkpoint inhibitor
Antibody Squamous cell carcinoma, Renal cell carcinoma PD-1 Phase 1 Y-Biologics HN21C1391
54 Preclinical study of IOH-001, a Bispecific Antibody immunotherapy targeting PD-L1 and CD47
Antibody TNBC PD-L1, CD47 Preclinical ImmuneOncia HN21C1388
55 Development of humanized antibody for lung cancer treatment targeting DDOST protein
Antibody Lung cancer DDOST Lead Hanyang University HN21C1351
56 Development of anti-HLA-G/CD3 T-cell engaging bispecific antibody for the treatment of CRC patients
Antibody Colorectal cancer HLA-G, CD3 Candidate Y-Biologics HN21C1337
57 Identification of leading substances for the treatment of esophageal cancer and breast cancer based on PTK7-neutralizing humanized antibodies
Antibody Esophageal squamous cell carcinoma, TNBC, PTK7 expression cancer PTK7 Lead Yonsei University HN21C1214
58 Production of non-clinical and clinical samples of TROP2-ADC for IND filing and approval, or technology transfer
Antibody Solid Tumor TROP2 Preclinical LegoChem Biosciences, Inc. HN21C1199
59 Lead Generation of DLL3-ADC for the Treatment of Small Cell Lung Cancer
Antibody Rare cancer DLL3 Lead IntoCell HN21C1082
60 Phase 1 clinical development of anti-cancer bispecific antibody ABL501 targeting LAG-3 and PD-L1
Antibody NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, Triple-Negative Breast Cancer, Ovarian cancer PD-L1, LAG-3 Phase 1 ABL Bio HN21C0979
61 NN3201, an IND-enabling study stage multimodal, cKIT-targeting ADC for SCLC, GIST, and AML
Antibody Gastrointestinal stromal tumor C-kit, microtuble inhibition에 의한 cell cycle arrest, apoptosis 유도 Preclinical Novelty Nobility Inc. HN21C0860
62 Development of a novel ADC for the treatment of glioblastoma
Antibody Glioblastoma FGFR3 Candidate Aimed Bio Inc. HN21C0803
63 Development of anti-VISTA antibody PMC-309 for the treatment of NSCLC
Antibody NSCLC VISTA Preclinical PharmAbcine Inc. HN21C0774
64 ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment
Antibody Solid Tumor B7-H4, 4-1BB Preclinical ABLBio HN21C0614
65 Next-generation anti-TIGIT antibody (7043H1E) with enhanced Fc function
Antibody Solid Tumor TIGIT Candidate HanAll BioPharma HN21C0596
66 Phase 1 clinical trial of CKD-702, bispecific antibody, in NSCLC
Antibody NSCLC c-MET, EGFR Phase 1 Chong Kun Dang pharmaceutical Corp. HN21C0551
67 A study on development of lead antibodies targeting an immune checkpoint inhibitor refractory factor for metastatic melanoma
Antibody Metastatic malignant melanoma Oncokine-2 Hit Korea university HN21C0486
68 Hit and lead compound discovery of antibody-drug conjugate (ADC) targeting Doppel, a tumor-specific molecule
Antibody Cancer Doppel Hit Seoul National University HN21C0264
69 Development of antibody-based therapeutics neutralizing a novel target for the treatment of metastatic colorectal cancer
Antibody Metastatic colorectal cancer CCSP-2 Hit ASAN Medical Center HN21C0207
70 Development of hit and lead asymmetric anti-CD20xCD55 bispecific antibodies containing Fc variants with maximized serum half-lives and effector functions for cancer therapy
Antibody Non-Hodgkin lymphoma, CLL CD20, CD55 Hit Korea University HN21C0103
71 Development of lead antibodies targeting an immune- checkpoint inhibitor refractory factor for metastatic non-small cell lung carcinoma
Antibody Lung cancer NSN-001 Lead NEX-I, Inc HN21C1323
72 Lead selection of PD-L1xCD3 targeted immuno-oncology (MB101) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, CD3 Lead MustBio Inc HN21C0985
73 Development of anti-PD-L1 x anti-SIRPα bispecific antibody that systemically activates both innate and adaptive anti-tumor immune system
Antibody Solid Tumor PD-L1, SIRPα Hit PharmAbcine Inc. HN21C0973
BACK